Laser Ablation for Thyroid Cancer

Overseen By R. Michael Tuttle, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Memorial Sloan Kettering Cancer Center

Disqualifiers: Non-PTC thyroid cancer, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 1

Duration: 1 day

10 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Percutaneous Laser Ablation (PLA) for thyroid cancer?

Research shows that Percutaneous Laser Ablation (PLA) is effective in treating various thyroid conditions, including benign thyroid nodules and papillary thyroid microcarcinoma, by reducing nodule size and treating cancerous nodules. This suggests that PLA could be a promising treatment for thyroid cancer. ^{1 2 3 4 5}

Is laser ablation safe for thyroid conditions?

Research on percutaneous laser ablation (PLA) for thyroid conditions, including benign nodules and papillary thyroid cancer, suggests it is generally safe. Studies have evaluated its safety over several years, indicating it is a viable option for treating these conditions. ^{1 5 6 7 8}

How is the treatment Percutaneous Laser Ablation (PLA) for thyroid cancer different from other treatments?

Percutaneous Laser Ablation (PLA) is unique because it uses laser energy to target and destroy thyroid tissue through the skin without surgery, making it less invasive than traditional surgical methods. It has been used for both benign and cancerous thyroid conditions, offering a non-surgical option for patients. ^{1 2 4 5 9}

What is the purpose of this trial?

The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.

Research Team

R. Michael Tuttle, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for adults with a small thyroid cancer (≤13mm) called papillary thyroid microcarcinoma, who haven't spread to lymph nodes or beyond the thyroid capsule. It's for those who've declined just watching the tumor and have certain cancer cell characteristics confirmed by tests.

Inclusion Criteria

My other vocal cord works fine before the procedure.

The size of the maximum diameter of something should be 13 millimeters or less.

Your medical scans do not show any signs of cancer spreading to the lymph nodes.

Exclusion Criteria

My cancer has spread to my lymph nodes.

Pregnancy

Your thyroid lesion has more than 25% cysts in it.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo percutaneous laser ablation (PLA) for papillary thyroid microcarcinoma

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

Multiple visits (in-person)

Treatment Details

Interventions

• Percutaneous Laser Ablation (PLA)

Trial Overview The study is testing percutaneous laser ablation (PLA), which uses lasers to destroy tumors without surgery, as a treatment option for removing tiny papillary thyroid cancers instead of traditional surgery.

Participant Groups

Group I: Participants with papillary microcarcinoma (PTMC) Experimental Treatment 1 Intervention

Participants with papillary microcarcinoma (PTMC) who have elected to proceed with thyroidectomy rather than an observational management approach will be considered as potential candidates for this trial.

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

References

1. United States pubmed.ncbi.nlm.nih.gov

Percutaneous laser ablation of cold benign thyroid nodules: a 3-year follow-up study in 122 patients. [2022]

2. England pubmed.ncbi.nlm.nih.gov

Benign thyroid nodules treatment using percutaneous laser ablation (PLA) and radiofrequency ablation (RFA). [2022]

3. Switzerland pubmed.ncbi.nlm.nih.gov

The feasibility and efficacy of ultrasound-guided percutaneous laser ablation for multifocal papillary thyroid microcarcinoma. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Treatment of Metastatic Lymph Nodes in the Neck from Papillary Thyroid Carcinoma with Percutaneous Laser Ablation. [2022]

5. Switzerland pubmed.ncbi.nlm.nih.gov

The value of ultrasound guided laser ablation in papillary thyroid recurrence carcinoma: A retrospective, single center study from China. [2022]

6. China pubmed.ncbi.nlm.nih.gov

[Ultrasound-guided percutaneous laser ablation for benign solid thyroid nodule: a pilot study]. [2016]

7. England pubmed.ncbi.nlm.nih.gov

Percutaneous laser ablation for treatment of locally recurrent papillary thyroid carcinoma [2019]

8. United States pubmed.ncbi.nlm.nih.gov

Long-Term Efficacy of Ultrasound-Guided Percutaneous Laser Ablation for Low-Risk Papillary Thyroid Microcarcinoma: A 5-Year Follow-Up Study. [2022]

9. United States pubmed.ncbi.nlm.nih.gov

Percutaneous laser ablation in the treatment of toxic and pretoxic nodular goiter. [2022]